Market news

Caris Life Sciences has surged off its May low near 14. The molecular research firm for drug companies might turn profitable this year.

Key TakeawaysSector Rally: Caris Life Sciences (CAI) stock jumped 9. 61% to close at $31 on Thursday, September 17, riding a Fed-driven market rally and a surge across AI-powered precision oncology peers.

Caris Life Sciences, Inc. (CAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Caris Life Sciences, Inc. (CAI) has an average rating of overweight and mean price target of $27.08,

Caris Life Sciences (CAI) is drawing fresh attention after announcing that its researchers will present seven lung cancer studies at the 2026 World Conference on Lung Cancer in Seoul this month. For investors, the World Conference presentations and August’s pancreatic cancer AI publication land against a mixed share price backdrop for Caris Life Sciences, with the stock down 28.06% on a 1 year total shareholder return basis but showing strong 90 day share price momentum of 55.33% and a 30 day...

Caris Life Sciences (NasdaqGS: CAI) announced plans to present seven major precision oncology studies at the IASLC 2026 World Conference on Lung Cancer. The company highlighted new data on molecular profiling and AI powered analysis for lung cancer care. Caris also published a validated AI driven method designed to help optimize first line pancreatic cancer treatment choices. For readers following how AI is reshaping cancer research and treatment, it can also be useful to look at other...

Caris Life Sciences,?Inc. (CAI) delivered earnings and revenue surprises of +100.00% and +14.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Caris Life Sciences, Inc. (Nasdaq: CAI), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended June 30, 2026.

Caris Life Sciences (NASDAQ:CAI) reported record clinical volume and raised its full-year revenue outlook after second-quarter revenue increased 45% from a year earlier, driven by growth in molecular profiling services, higher average selling prices and an expanding commercial organization. The com

Dublin, July 21, 2026 (GLOBE NEWSWIRE) -- The "Biomarker Collaboration and Licensing Deals 2016-2026" has been added to ResearchAndMarkets.com's offering.This report provides a comprehensive and structured analysis of 590+ biomarker collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.The definitive benchmark for biomarker dealmaking Biomarker partnering is driven by data, discovery, and precisi

Caris Life Sciences, NasdaqGS:CAI, has introduced in-house PTEN immunohistochemistry testing. The launch follows FDA approval of a biomarker guided therapy for PTEN deficient metastatic prostate cancer. The new PTEN IHC service is integrated into Caris' existing molecular profiling platform. For investors watching precision oncology, Caris Life Sciences, NasdaqGS:CAI, sits at the intersection of diagnostics and targeted treatment selection. The new PTEN IHC capability fits into the...

Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday, August 5, 2026.

Detailed price information for Caris Life Sciences Inc (CAI-Q) from The Globe and Mail including charting and trades.

Caris Life Sciences Inc. (NASDAQ:CAI) is one of the best IPO stocks with huge upside potential. On July 1, Caris Life announced the commercial launch of Caris Detect, a multi-cancer early detection blood test. By utilizing ultra-deep Whole Genome and Whole Transcriptome sequencing alongside advanced AI, the test identifies cancer signals by analyzing a comprehensive […]